↓ Skip to main content

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Overview of attention for article published in Journal for Immunotherapy of Cancer, December 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
1 news outlet
twitter
77 X users

Citations

dimensions_citation
224 Dimensions

Readers on

mendeley
110 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Published in
Journal for Immunotherapy of Cancer, December 2018
DOI 10.1186/s40425-018-0463-2
Pubmed ID
Authors

Fatima Karzai, David VanderWeele, Ravi A. Madan, Helen Owens, Lisa M. Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L. Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B. Trepel, Maria J. Merino, Ryan Dittamore, Jennifer Marté, Renee N. Donahue, Jeffrey Schlom, Keith J. Killian, Paul S. Meltzer, Seth M. Steinberg, James L. Gulley, Jung-Min Lee, William L. Dahut

X Demographics

X Demographics

The data shown below were collected from the profiles of 77 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 110 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 110 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 16%
Student > Ph. D. Student 12 11%
Student > Master 12 11%
Other 11 10%
Student > Bachelor 8 7%
Other 20 18%
Unknown 29 26%
Readers by discipline Count As %
Medicine and Dentistry 36 33%
Biochemistry, Genetics and Molecular Biology 13 12%
Agricultural and Biological Sciences 6 5%
Nursing and Health Professions 4 4%
Computer Science 3 3%
Other 11 10%
Unknown 37 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 54. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 June 2022.
All research outputs
#798,206
of 25,775,807 outputs
Outputs from Journal for Immunotherapy of Cancer
#194
of 3,513 outputs
Outputs of similar age
#17,737
of 448,430 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#2
of 63 outputs
Altmetric has tracked 25,775,807 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,513 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,430 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.